Core Insights - The "Jin Jie You Cu" event in Chengdu facilitates direct communication between enterprises and government departments, addressing challenges faced by the biopharmaceutical industry [1][6] - Chengdu's biopharmaceutical industry is experiencing rapid growth, with a market size exceeding 400 billion yuan and a strong focus on innovation and collaboration [7][8] Group 1: Event Overview - The "Jin Jie You Cu" event gathered over 30 enterprises, government officials, and industry experts to discuss challenges and solutions in the biopharmaceutical sector [1] - Companies like Kelun Pharmaceutical and Microchip Biotech highlighted the importance of direct dialogue with government representatives to resolve issues [1][6] Group 2: Company Challenges - Chengdu-based companies face difficulties in hospital admissions for their innovative products, with a call for policies to prioritize local medical devices [3][6] - Microchip Biotech emphasized the need for better access to clinical resources and support for innovative drug development [3][6] Group 3: Government Responses - Government departments responded to company concerns by outlining support for new drug research and addressing regulatory challenges [6] - The Chengdu Municipal Science and Technology Bureau is focusing on supporting projects that align with enterprise needs, particularly in high-end medical equipment [6] Group 4: Industry Development - Chengdu's biopharmaceutical industry is positioned for significant growth, with a focus on research and development, market expansion, and integration of medical and engineering sectors [7][8] - Recent policies aim to enhance the ecosystem for biopharmaceuticals, including financial incentives for innovative drug development [8][9]

Core Viewpoint - Microchip Biotech (688321) has experienced a slight decline in stock price, closing at 30.41 yuan, down 1.49% from the previous week, with a current market capitalization of 12.401 billion yuan [1] Group 1: Clinical Research Updates - The Phase II clinical trial of Xioroni for pancreatic cancer has enrolled 42 patients, with a 6-month progression-free survival (PFS) rate of nearly 80%, showing better efficacy compared to historical chemotherapy results [3][9] - The sales of Sigleth sodium increased by 125.7% in the first half of 2025, with a year-on-year growth rate of 136.1% in the first three quarters, attributed to successful self-operated and commissioned sales models [4][9] - The Phase III clinical trial of Sidabamine for colorectal cancer has enrolled over 300 patients, leading the domestic competition in similar indications, with expectations to complete most patient enrollments by 2025 [7][9] Group 2: Company Announcements - Microchip Biotech plans to repurchase shares amounting to no less than 10 million yuan and no more than 15 million yuan, with a repurchase price not exceeding 47.46 yuan per share, within a 12-month period [10] - The company has completed GMP compliance checks for the third production line of Sigleth sodium and is advancing GMP certification for the new formulation line, with plans to add a production capacity of 1.2 billion tablets by 2027 [6][9] - The top ten shareholders include Boao Biological Group, holding 30,627,198 shares, representing 7.51% of the total shares [8]

Group 1 - Company plans to raise no more than 3.6 billion yuan through a private placement to fund seven projects, including a 500,000 kW green power project in Inner Mongolia [1] - Company has received acceptance for a clinical trial application for its self-developed drug for metastatic pancreatic ductal adenocarcinoma [1] - Company intends to establish a joint venture to implement a high-quality gallium arsenide chip construction project with a total investment of 272 million yuan [2] Group 2 - Company reported a revenue of 142 million yuan from pig sales in October, with a total sales volume of 162,800 pigs [3] - Company signed an annual procurement contract to supply 870,000 tons of electrolyte products from 2026 to 2028 [5] - Company plans to reduce its shareholding by up to 3% through various trading methods [7] Group 3 - Company intends to purchase 100 hydrogen fuel cell vehicles for a total price of 78.32 million yuan [9] - Company plans to acquire a 51% stake in a semiconductor equipment company for 510 million yuan [10] - Company has regained eligibility to participate in military procurement activities after being removed from the banned list [12] Group 4 - Company plans to establish a joint venture with state-owned funds for rural development with a total registered capital of 2.87 billion yuan [14] - Company reported a revenue of 1.918 billion yuan from pig sales in October, with a significant year-on-year increase [16][17] - Company plans to distribute a cash dividend of 0.01 yuan per share, totaling 7.9801 million yuan [18] Group 5 - Company has submitted an application for H-share listing on the Hong Kong Stock Exchange [19] - Company received approval for its convertible bond issuance application [20] - Company plans to establish a wholly-owned subsidiary with an investment of 70 million yuan focused on innovative medical research [22] Group 6 - Company reported a 33.87% year-on-year increase in sales volume for October [26] - Company has received a product designation from a leading new energy vehicle brand, with an expected total revenue of approximately 470 million yuan [28] - Company has initiated a key Phase III clinical trial for an innovative eye drop treatment for moderate to severe dry eye syndrome [30] Group 7 - Company reported a total automobile sales volume of 170,700 units in October, a year-on-year decrease of 8.1% [30] - Company plans to invest 16 million USD in establishing a production base in Vietnam [33] - Company has received a warning letter from the regulatory authority due to a breach of commitment by its controlling shareholder [52]

Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, driven by the strong performance of its core products, Sidabenan and Siglecatin [1] - The company’s third-quarter results showed a remarkable year-on-year growth in both revenue and net profit, attributed to successful sales strategies and the inclusion of Sidabenan in medical insurance [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 674 million yuan, a year-on-year increase of 40.12%, with Sidabenan sales up 18.76% and Siglecatin sales up 136.13% [1] - The net profit attributable to the parent company for the same period was 71 million yuan, reflecting a year-on-year growth of 238.53%, while the net profit excluding non-recurring items was 58 million yuan, up 201.17% [1] - In Q3 2025, the company reported a revenue of 268 million yuan, a 49.51% increase year-on-year, and a net profit of 41 million yuan, which is a staggering 508.54% increase year-on-year [1] Clinical Developments - The Sidabenan combination therapy was included in the CSCO treatment guidelines with a top-level I recommendation, indicating strong clinical support [2] - The DEB study results showed a 54-month event-free survival rate of 52.5% for the treatment group, significantly better than the control group, enhancing the efficacy of first-line treatment for double-expressing DLBCL [2] - Ongoing clinical trials for Sidabenan in various cancer treatments are progressing well, with significant patient enrollment expected to be completed by 2025 [3] Future Projections - The company forecasts revenues of 935 million yuan, 1.42 billion yuan, and 2.03 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 42.14%, 51.78%, and 43.23% [4] - Projected net profits for the same years are 102 million yuan, 126 million yuan, and 180 million yuan, with growth rates of 188.63%, 23.78%, and 43.60% [4]

Core Viewpoint - Micron Biomedical has received the acceptance notice for the clinical trial application of its self-developed Xioroni capsules for the treatment of metastatic pancreatic ductal adenocarcinoma from the National Medical Products Administration [2] Group 1 - The clinical trial application for Xioroni capsules has been officially accepted, indicating progress in the drug development process [2] - This development highlights the company's commitment to advancing innovative treatments in oncology [2]

证券代码：688321 证券简称：微芯生物 公告编号：2025-070 深圳微芯生物科技股份有限公司 自愿披露关于西奥罗尼胶囊治疗转移性胰腺导管腺癌临床 试验申请获得受理的公告 1、产品名称：西奥罗尼胶囊 受理号：CXHL2501217、CXHL2501219 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳微芯生物科技股份有限公司（以下简称"公司"）近日收到国家药品监 督管理局药物审评中心（以下简称"国家药监局药审中心"）签发的境内生产药 品注册临床试验的《受理通知书》，公司自主研发的西奥罗尼胶囊治疗转移性胰 腺导管腺癌的临床试验申请获得受理。 本次申请为新药临床试验申请，在临床试验申请获得受理后，自受理之日起 60 日内未收到国家药监局药审中心的否定或质疑意见的，公司便可以按照提交 的方案开展临床试验。临床试验能否最终开展存在不确定性，敬请广大投资者注 意防范投资风险，谨慎决策。现将相关情况公告如下： 一、药品基本情况 特此公告。 受理日期：2025 年 11 月 06 日 适应症：西奥罗尼联合 P ...

Core Viewpoint - Micron Biologics (688321.SH) has received the acceptance notice for the clinical trial application of its self-developed drug, Xioroni capsules, for the treatment of metastatic pancreatic ductal adenocarcinoma from the National Medical Products Administration (NMPA) [1] Group 1: Drug Development - Xioroni is a novel small molecule anti-tumor drug with a unique chemical structure, developed independently by the company and protected by global intellectual property rights [1] - The drug exhibits a multi-pathway anti-tumor mechanism by inhibiting multiple kinase targets, including Aurora B, CSF1R, and VEGFR/PDGFR/c-Kit, providing comprehensive anti-pancreatic cancer effects [1] - Xioroni has shown significant synergistic inhibitory effects on pancreatic cancer growth when used in combination with the chemotherapy drug Gemcitabine [1] Group 2: Clinical Trial Results - Phase II clinical follow-up data indicates that Xioroni combined with standard AG chemotherapy (albumin-bound paclitaxel and Gemcitabine) has better objective response rates, disease control rates, and progression-free survival compared to historical data of AG chemotherapy [2] - The safety and tolerability of Xioroni in patients are reported to be good [2] - The drug is expected to further improve clinical efficacy and extend survival time for patients with advanced pancreatic cancer when combined with PD-1 monoclonal antibodies and chemotherapy [2]

Core Viewpoint - Microchip Biotech (688321.SH) has received the acceptance notice for the clinical trial application of its self-developed Xioroni capsules for the treatment of metastatic pancreatic ductal adenocarcinoma from the National Medical Products Administration's Drug Evaluation Center [1] Group 1 - The company has recently announced the acceptance of its clinical trial application [1] - The clinical trial is focused on a new drug aimed at treating a specific type of cancer, namely metastatic pancreatic ductal adenocarcinoma [1]

Core Points - The company plans to repurchase shares amounting to no less than RMB 10 million and no more than RMB 15 million [1] - The source of funds for the repurchase will be the company's own funds and a special loan for share repurchase [1][7] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1][5] - The maximum repurchase price is set at RMB 47.46 per share, which does not exceed 150% of the average trading price over the last 30 trading days prior to the board's decision [1][6] Repurchase Plan Details - The repurchase will be conducted through the Shanghai Stock Exchange trading system via centralized bidding [2][6] - The implementation period for the repurchase is within 12 months from the board's approval date [3][6] - There are currently no plans for share buybacks or sales by directors, supervisors, or senior management in the next three to six months [3][10] - The company has a shareholder, Bio-Ocean Group Co., Ltd., that is executing a disclosed share reduction plan [3][10] Financial Impact - The estimated repurchase amount of RMB 15 million represents approximately 0.41% of total assets, 0.91% of net assets, and 1.12% of current assets as of September 30, 2025 [8] - The company's debt-to-asset ratio is 54.42%, and the repurchase will not significantly impact its debt repayment ability [9] - The share repurchase is not expected to change the company's control structure or affect its listing status [9] Governance and Compliance - The proposal for the share repurchase was made by the chairman, Xianping Lu, based on confidence in the company's future and value [11][12] - The board's decision to repurchase shares was unanimously approved with 8 votes in favor [5] - The company has established a special securities account for the repurchase [18]

Summary of Stock Buybacks and Sell-offs on November 5 Buyback Activities - Kweichow Moutai plans to repurchase shares worth between 1.5 billion to 3 billion yuan and subsequently cancel them [2] - Kaili Medical's directors and senior management have increased their holdings in the company [2] - Hualan Biological plans to increase its holdings by 30 million to 60 million yuan [2] - Microchip Biotech intends to repurchase shares worth between 10 million to 15 million yuan [2] Sell-off Activities - Shangda Co. plans to reduce its holdings by up to 3.90% [3] - Xinjiang Communications Construction's major shareholder, TBEA Group, intends to reduce its holdings by up to 2.88% [3] - Ocean Motor's directors and executives plan to collectively reduce their holdings by up to 0.0361% [3] - Zhongchao Holdings' director plans to reduce his holdings by up to 0.0038% [3] - Del Future's directors and executives plan to collectively reduce their holdings by up to 0.0829% [3] - Jinbei Electric's shareholders plan to reduce their holdings by up to 1.77% [3] - Tianyi Co. and specific shareholders plan to reduce their holdings by up to 1% [3] - Kangsheng Co.'s shareholder Jiangsu Ruijin plans to reduce his holdings by up to 1% [3] - Ankai Bus's major shareholder plans to reduce his holdings by up to 1% [3] - Defang Nano's shareholder has completed his reduction plan [3] - Xiamen Construction's second-largest circulating shareholder has recently reduced his holdings by 17.74 million shares [3] - Hanbo High-tech's directors, executives, and shareholders plan to collectively reduce their holdings by up to 0.12% [3] - Haoliang Data's director plans to reduce his holdings by up to 0.0085% [3] - Zunming Co.'s actual controller and major shareholders plan to reduce their holdings [3] - Kaimete Gas's shareholders and concerted actors plan to reduce their holdings by up to 3% [3] - Chuangjiang New Materials' director plans to reduce his holdings by up to 0.13% [3] - Shutaishen's shareholder plans to reduce his holdings by up to 1% [3] - Wentai Technology's second-largest shareholder plans to reduce his holdings by up to 3% [3] - Kecuan Technology's controlling shareholder plans to reduce his holdings by up to 3% [3] - Shenma Power's actual controller has reduced his holdings by 1% between September 17 and November 5 [3] - Sanjiang Shopping's second-largest shareholder plans to reduce his holdings by up to 3% [3] - Chenguang New Materials' shareholder plans to reduce his holdings by up to 0.96% [3] - Zhiyang Innovation's directors and executives plan to collectively reduce their holdings by up to 0.52% [3] - Zhenhua Co. has seen two directors collectively reduce their holdings by 59,000 shares during the recent stock trading fluctuations [3] - Anbiping's shareholders plan to collectively reduce their holdings by up to 1% [3]